EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Other Sources: 3

NMN (nicotinamide mononucleotide)

Also called: nicotinamide mononucleotide, beta-nicotinamide mononucleotide, β-NMN

Nicotinamide mononucleotide (NMN) is a precursor of the coenzyme NAD+ and is used as an oral dietary supplement. Human trials so far have been short, lasting 14 days to 24 weeks.

Category
Other
Forms
Beta-nicotinamide mononucleotide (oral)
Strongest evidence
C Limited
Reviewed
2026-10-28

Class 1 Well studied in people. A 2026 meta-analysis (Nutrients) included 15 RCTs of oral NMN versus control, 3 of them using MIB-626, a microcrystalline NMN preparation; 10 trials (383 participants) contributed to the safety analyses. [1]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

3 topics studied2 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what NMN (nicotinamide mononucleotide) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for NMN (nicotinamide mononucleotide), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Body weight, glucose and blood lipids in adultsCA meta-analysis of 15 randomized trials found no significant effects on body weight, BMI, fasting glucose, HbA1c or lipids; insulin resistance (HOMA-IR) showed a non-significant downward trend. [1]
Blood pressure in adultsCIn the 2026 Yang meta-analysis of 15 randomized trials, systolic blood pressure did not change significantly; diastolic pressure decreased slightly. Larger, longer trials are needed. [1]
Muscle mass and function in adults over 60CA meta-analysis of randomized trials found no significant effects on skeletal muscle index, grip strength, gait speed or chair-stand time; NMN did not improve knee-extension strength. [2]
Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • 250–2,000 mg/day for 14 days to 24 weeks in randomized trials. [1]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    11 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • In short-term trials, NMN did not increase overall or serious adverse events or withdrawals and did not significantly raise liver enzymes (ALT, AST); long-term safety is not established. [1]
Regulation

Regulatory status

  • US: on October 11, 2022, FDA wrote to Inner Mongolia Kingdomway (NDI 1259) that NMN is excluded from the definition of a dietary supplement. [3]
  • US: on September 29, 2025, responding to a citizen petition (docket FDA-2023-P-0872), FDA reversed that position: "we now conclude that NMN is not excluded from the definition of dietary supplement under section 201(ff)(3)(B)," because NMN was marketed as a supplement before its authorization for investigation as a new drug. [3]
  • US: the same letter notes that an NDI acknowledgment letter is not an independent FDA finding that the ingredient is safe, and that the government may act to remove adulterated dietary supplements from the market. [3]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • β-Nicotinamide mononucleotide (NMN) Niacin-like compound (NIH ODS); a mononucleotide of nicotinamide [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 11 entries naming nicotinamide mononucleotide (NMN or β-NMN) (earliest NDI 1174 submitted 2020-08-25; most recent NDI 1444 submitted 2025-11-17). A further entry, NDI 1451 (submitted 2026-02-11), names reduced β-nicotinamide mononucleotide, calcium salt. Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P4]
  • US: on September 29, 2025, responding to a citizen petition (docket FDA-2023-P-0872), FDA concluded that NMN is not excluded from the definition of dietary supplement under section 201(ff)(3)(B), reversing its 2022 position. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC carcinogenicity evaluation of nicotinamide mononucleotide was found (IARC Monographs list of classifications checked 2026-10-29). [P5]
  • No NTP technical report on nicotinamide mononucleotide was found (NTP technical reports list checked 2026-10-29). [P6]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination of each component that is a dietary ingredient, before use — Required by 21 CFR 111.75(a)(1)(i); a manufacturer may petition for an exemption from this testing under 111.75(a)(1)(ii). [P7]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • Single oral doses of 100, 250 and 500 mg NMN in 10 healthy men: plasma N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-5-carboxamide (nicotinamide metabolites) increased significantly and dose-dependently over 5 hours. [P3]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. NIH Office of Dietary Supplements. Niacin: Fact Sheet for Health Professionals (updated November 18, 2022), 2022-11-18. ods.od.nih.gov
  2. U.S. FDA, Human Foods Program (D. Prater). Letter responding to the NPA and ANH-USA citizen petition on beta-nicotinamide mononucleotide (NMN), docket FDA-2023-P-0872 (posted to the docket September 29, 2025), 2025-09-29. downloads.regulations.gov
  3. Irie J, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J 2020;67(2):153-160 (PMID 31685720), 2020-02-28. pubmed.ncbi.nlm.nih.gov
  4. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  5. IARC Monographs. List of Classifications (accessed October 29, 2026), 2026-10-29. monographs.iarc.who.int
  6. National Toxicology Program. Technical Reports (TR) list (accessed October 29, 2026), 2026-10-29. ntp.niehs.nih.gov
  7. eCFR. 21 CFR 111.75 (title 21 displayed up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources

Sources

  1. Yang W, et al. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients 2026;18(14):2251 (PMID 42514320), 2026-07-10. pubmed.ncbi.nlm.nih.gov
  2. Prokopidis K, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2025;16(3):e13799 (PMID 40275690), 2025-06. pubmed.ncbi.nlm.nih.gov
  3. U.S. FDA, Human Foods Program (D. Prater). Letter responding to the NPA and ANH-USA citizen petition on beta-nicotinamide mononucleotide (NMN), docket FDA-2023-P-0872 (posted to the docket September 29, 2025), 2025-09-29. downloads.regulations.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.